Evidence map›Paper›PMID 40298171›Full record

ArticleCancer research communications2025

Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2.

Allison W Kurian, Elisha Hughes, Ryan Bernhisel, Eudora Hu, Eric C Polley, Siddhartha Yadav, Chunling Hu, Jennifer L Caswell-Jin, Esther M John, Aladdin H Shadyab and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Allison W KurianDepartment of Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-6175-9470
Elisha HughesMyriad Genetics, Salt Lake City, Utah.ORCID 0000-0002-3145-3913
Ryan BernhiselMyriad Genetics, Salt Lake City, Utah.ORCID 0000-0001-6437-6929
Eudora HuMyriad Genetics, Salt Lake City, Utah.ORCID 0009-0003-5247-4136
Eric C PolleyDepartment of Public Health Services, University of Chicago, Chicago, Illinois.ORCID 0000-0002-5152-8740
Siddhartha YadavMayo Clinic, Rochester, Minnesota.ORCID 0000-0003-4630-9903
Chunling HuMayo Clinic, Rochester, Minnesota.ORCID 0000-0002-6814-4639
Jennifer L Caswell-JinDepartment of Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-5711-8355
Esther M JohnDepartment of Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-3259-8003
Aladdin H ShadyabDivision of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California.ORCID 0000-0002-9693-0522
Rowan ChlebowskiThe Lundquist Institute, Torrance, California.ORCID 0000-0002-4212-6184
Rami NassirDepartment of Pathology, School of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.ORCID 0000-0001-9914-7851
Peter KraftNational Cancer Institute, NIH, Rockville, Maryland.ORCID 0000-0002-4472-8103
Marcia L StefanickDepartment of Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-0284-6996
Fergus J CouchMayo Clinic, Rochester, Minnesota.ORCID 0000-0001-9417-9985

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
NCI NIH HHS P50 CA116201NHLBI NIH HHS HHSN268201600001CNHLBI NIH HHS HHSN268201600002CNHLBI NIH HHS HHSN268201600003CNHLBI NIH HHS HHSN268201600004CNHLBI NIH HHS HHSN268201600018C
6 · The paper itself

Abstract

significanceThere is limited information on whether established risk factors increase breast cancer risk from PVs. In the WHI, PV carriers had no substantial (≥2-fold) increase with most risk factors, except potentially MHT in ATM or CHEK2 carriers. The results may inform counseling and research on MHT.

Indexed as

Breast NeoplasmsCheckpoint Kinase 2AdultAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinBRCA2 ProteinFanconi Anemia Complementation Group N ProteinFemaleGenetic Predisposition to DiseaseHumansMiddle AgedRisk FactorsAtaxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCheckpoint Kinase 2CHEK2 protein, humanFanconi Anemia Complementation Group N ProteinPALB2 protein, human

Identifiers

PMID40298171
PMCPMC12067184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.